The HBV Specially-Related Long Noncoding RNA HBV-SRL Involved in the Pathogenesis of Hepatocellular Carcinoma
Table 1
Relationship between the HBV-SRL expression and clinical-pathologic features.
Clinical feature
Low (n = 111)
High (n = 111)
value
Age, year
0.592
Mean (SD)
51.05 (10.4)
50.68 (10.33)
Sex, no. (%)
0.271
Male
97 (97.4)
102 (91.9)
Female
14 (12.6)
9 (8.1)
HBe antigen, no. (%)
0.767
Negative
78 (70.3)
80(72.1)
Positive
33 (29.7)
31 (27.9)
HBs antigen, no. (%)
0.695
Negative
14 (12.6)
16 (14.4)
Positive
97 (87.4)
95 (85.6)
Liver cirrhosis, no. (%)
0.499
No
7 (6.3)
10 (9.0)
Yes
104 (93.7)
101 (91.0)
Tumor size, no. (%)
0.412
≤5 cm
48 (43.2)
42 (37.8)
>5 cm
63 (56.8)
69 (62.2)
Tumor number, no. (%)
0.686
Single
96 (86.5)
98 (88.3)
Multiple
15 (13.5)
13 (11.7)
Microvascular invasion, no. (%)
0.652
Absent
82 (73.9)
79 (71.2)
Present
29 (26.1)
32 (28.8)
Tumor encapsulation, no. (%)
0.044
No
33 (29.7)
49 (44.1)
Incomplete
39 (35.1)
25 (22.5)
Complete
39 (35.1)
37 (33.3)
Portal vein tumor thrombus, no. (%)
0.187
No
98 (88.3)
91 (82.0)
Yes
13 (11.7)
20 (18.0)
Ascites, no. (%)
0.075
No
102 (91.9)
108 (97.3)
Yes
9 (8.1)
3 (2.7)
Alpha-fetoprotein, no. (%)
0.779
Negative, ≤20 (ng/ml)
38 (34.2)
40 (36.0)
Positive, >20 (ng/ml)
73 (65.8)
71 (64.0)
HBV DNA, no. (%)
0.021
≤10000 (copies/ml)
72 (64.9)
55 (49.5)
>10000 (copies/ml)
39 (35.1)
56 (50.5)
Serum bilirubin, no. (%)
0.652
≤18.8 (μmol/l)
79 (71.2)
82 (73.9)
>18.8 (μmol/l)
32 (28.8)
29 (26.1)
Serum albumin, no. (%)
0.196
≤40 (g/l)
7 (6.3)
3 (2.7)
>40 (g/l)
104 (93.7)
108 (97.3)
Serum prealbumin, no. (%)
0.324
≤170 (mgl)
42 (37.8)
35 (31.5)
>170 (mg/l)
69 (62.2)
76 (68.5)
Alanine aminotransferase, no. (%)
0.419
≤41 (U/liter)
63 (56.8)
57 (51.4)
>41 (U/liter)
48 (43.2)
54 (48.6)
Aspartate aminotransferase, no. (%)
0.502
≤37 (U/liter)
52 (46.8)
57 (51.4)
>37 (U/liter)
59 (53.2)
54 (48.6)
value <0.05 was considered to indicate statistical significance. values were calculated using Fisher’s exact test, except for age, which was calculated with an unpaired t test.
